3.1. epidemiology. prostate cancer (pca) second commonly diagnosed cancer men, estimated 1.4 million diagnoses 375,000 deaths worldwide 2020 . europe, frequently diagnosed cancer men third cancer-related cause death men . sr autopsy studies reported prevalence pca age < 30 years 5% (95% confidence interval [ci]: 3–8%), increasing odds ratio (or) 1.7 (1.6–1.8) per decade, prevalence 59% (48–71%) age > 79 years . variation frequency autopsy-detected pca men different ethnical backgrounds geographical areas (e.g., 83% white us males vs. 41% japan age 71–80) . regarding incidence pca diagnosis, variation even pronounced different geographical areas, driven rate prostate-specific antigen (psa) testing influenced (inter)national organisations recommendations screening (see section 5.1) . highest australia/new zealand northern america (age-standardised rates [asr] per 100,000 111.6 97.2, respectively), western northern europe (asrs 94.9 85, respectively). incidence low eastern south-central asia (asrs 10.5 4.5, respectively), rising . rates eastern southern europe low also shown steady increase . besides psa testing, incidence also dependent age population, geography ethnicity. relatively less variation mortality rates worldwide, although rates generally high populations african descent (e.g., caribbean: asr 29 sub-saharan africa: asrs ranging nineteen fourteen), intermediate usa low asia (south-central asia: asr 2.9) . mortality due pca decreased western nations magnitude reduction varies countries .